Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 18/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8129 | 1.00 | METAP2 (0.75) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL9551658 | 0.99 | METAP2 (0.74) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Biphenyl SCHEMBL9323135 | 0.94 | METAP2 (0.68) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL2552868 | 0.93 | METAP2 (0.66) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL8503660 | 0.91 | METAP2 (0.63) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL20658108 | 0.90 | METAP2 (0.61) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| SCHEMBL1245783 | 0.89 | METAP2 (0.61) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL15263951 | 0.86 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL12526078 | 0.86 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL6953272 | 0.86 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-2317845-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | Zafgen, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010009374-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN, INC. (US) | 2010-01-21 | — | — | WO | disclosed |